Monday, June 10, 2019 - The Trump administration's plan to end HIV in the United States and globally has taken a giant step in what may be the right direction. Gilead Science is giving away 200,000 doses of Truvada antiviral HIV prevention drug to individuals each year for the next 10-15 years forgoing a potential profit, of $20,000 per patient per year. Even so, providing Truvada to low-income and uninsured individuals appears to be a win-win for potentially ending the Aids epidemic as well as ensuring that Gilead Sciences, maker of Truvada, remains profitable for decades into the future. Over 2 million individuals in the United States will be eligible to get the drug for free every year until the year 2030. The agreement came as a result of direct negotiations between the Trump administration and Gilead according to Alex Azar, Secretary of Health and Human Services (HHS). Truvada is a pre-exposure prophylaxis (PrEP) medication used to prevent HIV and has a 97 percent effective rate of success when taken on a regular basis. Truvada lawyers handling kidney and bone cases related to Truvada, Viread, Stribild, Atripla, Symfi Lo, AccessPak for HIV PEP expanded with Kaletra, AccessPak for HIV PEP expanded with Viracept, Complera, Cimduo, or Genvoya help individuals recover the compensation they need and deserve, while holding companies accountable for wrongdoing and harm.
While some in government are ecstatic over the commitment to donate such a large quantity of the drug, others feel that it the drug's price that has kept it out of the hands of low-income and uninsured people in the first place and has unnecessarily extended the life of the disease. Daniel O'Day, the CEO of Gilead Sciences was recently hauled before Congress to give testimony in an attempt to justify Truvada's high price tag and was accused of using anti-competitive tactics to keep prices artificially high. Freshman congresswoman Alexandria Ocasio-Cortez, D-N.Y questioned Day as to why when the company was making over $3 billion per year in profits annually, and a total of $36 billion in revenues for the company since 2004, the company could justify charging the high price. "People are dying because of it, and there's no enforceable reason for it," said Cortez who noted that US government scientist actually discovered Tenofovir disoproxil a.k.a., Truvada. Day countered with the argument that in a capitalist society only the potential of earning unlimited profits would provide venture capitalists the incentive to take the risks inherent new drug development, a point that fell on deaf ears to Democrats but rang only too true to the Trump administration, defenders of the status quo and the art of the deal.
The Trump administration plan appears to be a workable compromise that aims to provide Gilead Sciences with a steady stream of revenues for the next 10-15 years while at the same time getting the drug into the hands of those who need it the most, albeit very gradually. Gilead sciences wins, as does Democrats in Congress that claim to put the welfare of people over what they consider to be corporate greed. The only people that lose are the 90% of low-income and uninsured people that cannot get the drug immediately and potentially contract the disease.
OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The firm has represented thousands of persons in these and other products liability litigation, including DePuy hip replacement systems, which settled for $2.5 billion and Pradaxa internal bleeding, which settled for $650 million. The Onder Law Firm won over $300 million in four talcum powder ovarian cancer lawsuits in St. Louis to date and other law firms throughout the nation often seek its experience and expertise on complex litigation.